First-in-man Clinical Trial to Assess Safety and Tolerability of CEB-01 PLGA Membrane in Patients With Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma After Surgery
Latest Information Update: 23 Feb 2026
At a glance
- Drugs SN 38 (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Soft tissue sarcoma; Solitary-fibrous-tumour
- Focus Adverse reactions; First in man
- Sponsors Cebiotex
Most Recent Events
- 19 Feb 2026 Status changed from active, no longer recruiting to completed.
- 04 Jun 2024 Results (n=14) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 27 Mar 2024 Planned End Date changed from 15 Mar 2024 to 15 May 2025.